Q3 2025 EPS Estimates for Editas Medicine, Inc. (NASDAQ:EDIT) Increased by Analyst

Editas Medicine, Inc. (NASDAQ:EDIT) – Investment analysts at Zacks Research increased their Q3 2025 earnings per share estimates for Editas Medicine in a report issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now forecasts that the company will earn ($0.74) per share for the quarter, up from their previous estimate of ($0.75). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.61) per share. Zacks Research also issued estimates for Editas Medicine’s Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.04) EPS, Q1 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.53) EPS.

EDIT has been the topic of several other research reports. JPMorgan Chase & Co. raised their price target on Editas Medicine from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Tuesday, February 27th. Barclays raised their price target on Editas Medicine from $10.00 to $11.00 and gave the company an “equal weight” rating in a report on Thursday, February 29th. StockNews.com upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Finally, Citigroup increased their target price on Editas Medicine from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Editas Medicine has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Editas Medicine Stock Up 1.9 %

Editas Medicine stock opened at $5.32 on Friday. The business’s 50-day simple moving average is $7.52 and its 200 day simple moving average is $8.32. The stock has a market cap of $437.52 million, a price-to-earnings ratio of -2.60 and a beta of 2.01. Editas Medicine has a 12-month low of $5.11 and a 12-month high of $11.91.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.29. The business had revenue of $60.00 million for the quarter, compared to analysts’ expectations of $4.84 million. Editas Medicine had a negative return on equity of 42.95% and a negative net margin of 196.12%. The firm’s quarterly revenue was up 817.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.88) earnings per share.

Insider Transactions at Editas Medicine

In other news, CEO Gilmore Neil O’neill sold 77,824 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $9.42, for a total transaction of $733,102.08. Following the sale, the chief executive officer now owns 327,470 shares of the company’s stock, valued at $3,084,767.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Gilmore Neil O’neill sold 77,824 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $9.42, for a total transaction of $733,102.08. Following the sale, the chief executive officer now owns 327,470 shares of the company’s stock, valued at $3,084,767.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Baisong Mei sold 20,327 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $9.42, for a total value of $191,480.34. Following the sale, the senior vice president now directly owns 141,543 shares in the company, valued at approximately $1,333,335.06. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Editas Medicine

A number of hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. raised its position in Editas Medicine by 49.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 57,033 shares of the company’s stock valued at $423,000 after buying an additional 18,745 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in Editas Medicine in the 1st quarter valued at approximately $1,097,000. Virtu Financial LLC acquired a new stake in Editas Medicine in the 4th quarter valued at approximately $748,000. Public Employees Retirement System of Ohio acquired a new stake in Editas Medicine in the 4th quarter valued at approximately $137,000. Finally, Seven Eight Capital LP acquired a new stake in Editas Medicine in the 4th quarter valued at approximately $1,482,000. Institutional investors and hedge funds own 71.90% of the company’s stock.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.